bluebird bio Inc (BLUE)

93.25
3.85 3.96
NASDAQ : Health Care
Prev Close 97.10
Open 96.20
Day Low/High 93.05 / 97.40
52 Wk Low/High 35.37 / 169.16
Volume 448.51K
Avg Volume 1.04M
Exchange NASDAQ
Shares Outstanding 45.59M
Market Cap 4.42B
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others

The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an...

Time to Take Profits in Bluebird Bio

Time to Take Profits in Bluebird Bio

This biotech has done well so far this year, but now it's time to lock in some gains.

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an...

Bluebird Bio Announces Topline Interim Clinical Data From Starbeam Study Of Lenti-D™ Drug Product In Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced topline...

Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease (SCD) At European Hematology Association (EHA) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced new data...

Bluebird Bio Announces Early Data From Phase 3 Northstar-2 (HGB-207) Study Of LentiGlobinTM Drug Product At European Hematology Association (EHA) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced early...

Bluebird Bio Appoints Two New Directors to its Board

Bluebird Bio Appoints Two New Directors to its Board

bluebird bio appointed John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to its Board of Directors.

Bluebird Bio Appoints John O. Agwunobi, M.D. And Douglas A. Melton, Ph.D. To Board Of Directors

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it...

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Gold Action Highlights Event Risk

Comey's Senate testimony looms.

Bluebird Bio Stock Upgraded at BMO

Bluebird Bio Stock Upgraded at BMO

Upcoming data readouts throughout the remainder of this year will 'provide investors with multiple opportunities for upside across TDT, SCD and myeloma,' BMO analyst Matt Luchini noted.

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel.

Bluebird Bio And Celgene Corporation Announce Updated Clinical Results From Ongoing First-in-Human Multicenter Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Relapsed/Refractory Multiple Myeloma At ASCO Annual Meeting

bluebird bio, Inc. (NASDAQ:BLUE), and Celgene Corporation (NASDAQ:CELG) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell...

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

100% response rate with zero relapses are the latest update from Bluebird's BB2121 study in multiple myeloma patients.

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.

Bluebird Bio To Present At Two Investor Conferences In June

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Announces Collaboration With Duke University's Robert J. Margolis, MD, Center For Health Policy On Value-Based Payment Framework For Gene Therapy

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will...

Bluebird Bio To Present New Data From LentiGlobinTM Clinical Studies At European Hematology Association (EHA) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data...

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.

Bluebird Bio To Present Updated Clinical Results From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At American Society Of Clinical Oncology (ASCO) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that updated...

Bluebird Bio Reports First Quarter 2017 Financial Results And Recent Operational Progress

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business...

Bluebird Bio Licenses Lentiviral Vector Patent Rights For Development And Commercialization Of Cell Therapies

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG.

Bluebird Bio Enters Lentiviral Vector Patent License Agreement With GlaxoSmithKline For Commercialization Of Gene Therapies

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GlaxoSmithKline Intellectual Property Development Limited (GSK).

Bluebird Bio To Present At Upcoming Investor Conferences

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Appoints New Senior Manufacturing And Corporate Development Executives

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal Of Medicine

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the...

Bluebird Bio To Present At Two Investor Conferences In March

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...